8-K: Kura Oncology Announces Positive Topline Results and FDA Feedback for Ziftomenib in AML

Kura Oncology and Kyowa Kirin announce positive topline results from the KOMET-001 trial and plans to initiate Phase 3 trials for ziftomenib in AML, with an NDA submission expected in Q2 2025.

Summary

• Kura Oncology and Kyowa Kirin announced positive topline results from the Phase 2 KOMET-001 trial of ziftomenib in relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML).
• The KOMET-001 trial achieved its primary endpoint of complete remission (CR) plus CR with partial hematological recovery (CRh), which was statistically significant.
• Kura is on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ziftomenib in the second quarter of 2025.
• The companies plan to initiate two Phase 3 trials in the second half of 2025 to evaluate ziftomenib in combination with intensive and non-intensive regimens in newly diagnosed NPM1-m and KMT2A-rearranged (KMT2A-r) AML.
• These trials, named KOMET-017-IC and KOMET-017-NIC, will assess dual-primary endpoints to support potential U.S. accelerated approval and full approval.
• Kura and Kyowa Kirin expect to present multiple clinical data updates from their ziftomenib AML program in 2025.
• Kura also expects to present updates from its KO-2806 and tipifarnib programs in 2025.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook with successful trial results, FDA feedback, and a clear path to potential commercialization. The collaboration with Kyowa Kirin and strong cash position further contribute to the positive sentiment.

Positives

• Positive topline results from the KOMET-001 trial indicate potential efficacy of ziftomenib in R/R NPM1-m AML.
• The FDA's positive feedback on the Phase 3 trial designs increases the likelihood of successful trials and potential approval.
• The collaboration with Kyowa Kirin provides financial support for the expansive AML development program.
• The company is on track to submit an NDA for ziftomenib in Q2 2025.
• The benefit-risk profile for ziftomenib is highly encouraging, and safety and tolerability were consistent with previous reports.

Negatives

• The document focuses on positive results and future plans, with no explicit negative aspects mentioned.
• The document does not mention any negative aspects.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Risks include the possibility that clinical trials may not be successful, the FDA may not agree with Kura's interpretation of data, and the company may face delays in clinical testing or regulatory approval.
• The company relies on third parties to conduct clinical trials and on outside financing to meet capital requirements.
• Unexpected adverse side effects or inadequate therapeutic efficacy of product candidates could delay or prevent regulatory approval or commercialization.

Future Outlook

Kura Oncology anticipates several milestones in 2025, including the NDA submission for ziftomenib, initiation of Phase 3 trials, and multiple data readouts across its pipeline programs. The company expects to present clinical data from ziftomenib, KO-2806, and tipifarnib programs.

Management Comments

• Our goal is to develop transformative therapies to extend and improve the lives of patients with cancer.

Industry Context

The announcement highlights the growing interest in menin inhibitors for AML treatment, particularly in NPM1-mutant and KMT2A-rearranged AML subtypes. The collaboration with Kyowa Kirin underscores the potential commercial value of ziftomenib. The focus on combination therapies in frontline settings reflects a broader trend in AML treatment to improve outcomes and reduce relapse rates.

Comparison to Industry Standards

• The document mentions analog pricing for recently approved products in the range of $36-40k per month, which is consistent with the pricing of other targeted therapies in hematologic malignancies.
• The potential peak sales for menin inhibitors in 1L AML are estimated to be >$7B/yr, reflecting the significant unmet need and large market opportunity in this patient population.
• The document references the VIALE-A trial and real-world evidence (RWE) cohort results published by Othman et al 2024, indicating that the company is incorporating current clinical practice and long-term follow-up data into its trial designs.

Stakeholder Impact

• Positive results and potential approval of ziftomenib could significantly benefit patients with AML, particularly those with NPM1-m mutations.
• The collaboration with Kyowa Kirin could lead to increased job opportunities and economic growth.
• Successful commercialization of ziftomenib would generate revenue for Kura Oncology and its shareholders.

Next Steps

• Submit NDA to the FDA for ziftomenib in R/R NPM1-m AML in Q2 2025.
• Present topline data from the KOMET-001 trial in Q2 2025.
• Initiate KOMET-017 Phase 3 trials in 1L NPM1-m and KMT2A-r AML in the second half of 2025.
• Present clinical data updates from ziftomenib, KO-2806, and tipifarnib programs throughout 2025.

Key Dates